Free Trial

Repligen Corporation $RGEN Stock Holdings Boosted by William Blair Investment Management LLC

Repligen logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • William Blair Investment Management increased its Repligen stake by 57.7% in the third quarter, adding 454,844 shares to hold 1.24 million shares valued at about $239 million.
  • Repligen reported quarterly EPS of $0.53, beating the $0.46 consensus estimate, while revenue rose 10.9% year over year to $209.31 million.
  • Analyst sentiment was broadly positive: Repligen had a “Moderate Buy” consensus rating and an average price target of $178.57, though one firm downgraded the stock to Sell.
  • Five stocks to consider instead of Repligen.

William Blair Investment Management LLC boosted its stake in Repligen Corporation (NASDAQ:RGEN - Free Report) by 57.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,243,415 shares of the biotechnology company's stock after purchasing an additional 454,844 shares during the period. Repligen comprises about 0.8% of William Blair Investment Management LLC's holdings, making the stock its 23rd largest holding. William Blair Investment Management LLC owned about 1.95% of Repligen worth $239,022,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in RGEN. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Repligen during the second quarter worth $52,000. CoreCap Advisors LLC increased its holdings in shares of Repligen by 1,275.0% during the third quarter. CoreCap Advisors LLC now owns 275 shares of the biotechnology company's stock worth $53,000 after buying an additional 255 shares in the last quarter. Harbor Investment Advisory LLC increased its holdings in shares of Repligen by 198.9% during the second quarter. Harbor Investment Advisory LLC now owns 523 shares of the biotechnology company's stock worth $71,000 after buying an additional 348 shares in the last quarter. Trust Co. of Vermont bought a new position in shares of Repligen in the 2nd quarter valued at $71,000. Finally, Allworth Financial LP bought a new position in shares of Repligen in the 2nd quarter valued at $71,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Stock Performance

Shares of RGEN opened at $167.79 on Monday. The firm has a market cap of $10.73 billion, a P/E ratio of -798.96, a price-to-earnings-growth ratio of 2.88 and a beta of 1.11. The company has a debt-to-equity ratio of 0.27, a quick ratio of 8.43 and a current ratio of 9.88. The business has a 50-day moving average of $177.15 and a 200 day moving average of $145.67. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $198.87.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, October 27th. The biotechnology company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.46 by $0.07. Repligen had a negative net margin of 1.47% and a positive return on equity of 5.49%. The company had revenue of $209.31 million during the quarter, compared to the consensus estimate of $206.70 million. During the same period last year, the firm earned $0.46 EPS. Repligen's revenue for the quarter was up 10.9% on a year-over-year basis. As a group, research analysts forecast that Repligen Corporation will post 2.07 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on RGEN shares. Weiss Ratings downgraded Repligen from a "hold (c)" rating to a "sell (d+)" rating in a report on Monday, November 2nd. Barclays boosted their price objective on shares of Repligen from $175.00 to $225.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 7th. Wells Fargo & Company increased their target price on shares of Repligen from $180.00 to $185.00 and gave the company an "overweight" rating in a research report on Thursday, July 30th. Royal Bank Of Canada increased their price target on Repligen from $185.00 to $200.00 and gave the stock an "outperform" rating in a report on Wednesday, October 28th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Repligen from $165.00 to $175.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Repligen presently has a consensus rating of "Moderate Buy" and a consensus price target of $178.57.

View Our Latest Analysis on Repligen

Repligen Company Profile

(Free Report)

Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company's offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.

Further Reading

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Repligen Right Now?

Before you consider Repligen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.

While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines